In The News - 2013

HyperBranch Announces Completion of Clinical Enrollment for FDA Pivotal Study

January 24, 2013   |   Durham, NC  

HyperBranch Medical Technology, Inc. announced today that it has completed patient enrollment in the Adherus Dural Sealant U.S. pivotal clinical trial, a controlled, randomized trial comparing the Adherus Dural Sealant in neurosurgery patients, to the only other approved sealant for these procedures. Over 240 patients were treated in the trial. Patients will be followed for four months to evaluate the safety and effectiveness of Adherus, following which, the data will be submitted to the FDA for review as part of the PMA submission.

See Full Press Release